MEDTR.E — Meditera Tibbi Malzeme Sanayi ve Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Market Cap
TRY3.30bn
Enterprise Value
TRY2.93bn
Revenue
TRY2.09bn

Annual income statement for Meditera Tibbi Malzeme Sanayi ve Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	359	376	1,596	2,097	2,094
Cost of Revenue
Gross Profit	164	166	681	929	827
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	265	296	1,214	1,708	1,866
Operating Profit	94.1	80.2	382	389	229
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	65.1	202	196	80.3	72.6
Provision for Income Taxes
Net Income After Taxes	60.4	168	114	37.4	70.3
Minority Interest
Net Income Before Extraordinary Items
Net Income	60.4	168	114	37.3	73.4
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	60.4	168	114	37.3	73.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.51	1.4	0.911	-0.367	0.638
Dividends per Share